Moleculin publishes cardiac safety analysis of Annamycin in five trials

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. META
3. ANT
4. SPY
5. CART
6. GMAB
7. FFAI
8. TSLA
9. FFR
10. AZN

Go back to Moleculin publishes cardiac safety analysis of Annamycin in five trials

Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine

September 28, 2026 7:00 AM EDT

        Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline limits

      Independent Cleveland Clinic cardio-oncology evaluation supports continued clinical development of Annamycin as a potentially safer anthracycline

HOUSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (Moleculin or the Company) today announced the publication of a peer-reviewed analysis of the cardiac safety of Annamycin (also known as L-Annamycin or naxtarubicin) in Frontiers in Cardiovascular Medicine. The publication, titled Cardiac safety of L-Annamycin: a pooled analysis of... More